Federal contractor · FRAMINGHAM, MA

KEPHERA DIAGNOSTICS LLC

No contract obligations recorded for KEPHERA DIAGNOSTICS LLC in FY2026. Since FY2018: $3.3M. It also received $1.3M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
LJFNSE6NM648
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 150KFY2018
  2. 300KFY2019
  3. 0FY2020
  4. 2.3MFY2021
  5. 0FY2023
  6. 300KFY2024
  7. 300KFY2025

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for KEPHERA DIAGNOSTICS LLC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

KEPHERA DIAGNOSTICS LLC received $1.3M in federal assistance in FY2026, on 9 actions (1 new awards), −73% vs FY2025. Its largest program was 93.837 · Cardiovascular Diseases Research ($1M).

Assistance · FY2026
$1.3M
New awards
1
Actions
9
Since FY2021
$16.8M

Assistance by fiscal year

  1. 1.3MFY2021
  2. -8.3FY2022
  3. 4.4MFY2023
  4. 5MFY2024
  5. 4.9MFY2025
  6. 1.3MFY2026

By type

  1. Grants$1.3M100%

Top programs

  1. 93.837 · Cardiovascular Diseases Research$1M77%
  2. 93.855 · Allergy and Infectious Diseases Research$303.3K23%

Awarding agencies

  1. National Institutes of Health$1.3M100%
    Department of Health and Human Services

Largest awards

  1. POINT-OF-CARE DIAGNOSTIC TEST FOR T. CRUZI (CHAGAS) INFECTION - PROJECT SUMMARY CHAGAS DISEASE, CAUSED BY INFECTION WITH THE PARASITE…$3.1M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Mar 30, 2023 – Jan 3, 2026· R44AI136172
  2. RAPID POINT-OF-CARE ASSAY FOR DIAGNOSIS OF NEUROCYSTICERCOSIS IN SEIZURE PATIENTS - PROJECT SUMMARY EPILEPSY, A DISORDER OF THE BRAIN…$3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· May 12, 2023 – Jan 30, 2026· R44AI149903
  3. BIOMARKER-BASED TEST OF CURE FOR CHAGAS DISEASE - PROJECT SUMMARY CHAGAS DISEASE, CAUSED BY INFECTION WITH TRYPANOSOMA CRUZI, IS THE MOST…$2.9M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 5, 2023 – Jun 3, 2026· R44AI147973
  4. HYBRID ELISA: SIMPLE AND SPECIFIC ONE-TIER ASSAY FOR LYME DISEASE - ABSTRACT LYME DISEASE, CAUSED BY INFECTION WITH THE SPIROCHETE BORRELIA…$2.8M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 11, 2023 – Jun 3, 2026· R44AI142903
  5. PEPTIDE-BASED ELISA FOR LABORATORY DIAGNOSIS OF SARCOIDOSIS - PROJECT SUMMARY SARCOIDOSIS IS A SYSTEMIC INFLAMMATORY DISEASE OF UNKNOWN…$2M
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Sep 14, 2025 – Sep 4, 2026· R44HL180181
  6. DIAGNOSTIC ASSAY FOR CONGENITAL CHAGAS DISEASE - PROJECT SUMMARY THIS PROJECT AIMS TO DEVELOP A DIAGNOSTIC TEST FOR CONGENITAL CHAGAS…$606.5K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Apr 26, 2024 – Jan 30, 2026· R43AI181234

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 3, 2026, loaded Oct 3, 2026 · FY2021–FY2026.

Subawards

Matched by Unique Entity ID: the first-tier subawards this organization reported as a prime recipient, and those primes reported paying it.

As a prime: who it pays · FY2026

No subawards reported as a prime in FY2026.

As a sub-recipient: who pays it · FY2026

No subawards reported to it in FY2026.

By fiscal year

  • FY2023: $366.7K paid out · $0 received
  • FY2024: $1.1M paid out · $0 received
  • FY2025: $524.3K paid out · $0 received

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 3, 2026, loaded Oct 3, 2026 · Subawards loaded from FY2021.

Teaming partners

Companies this company reported paying, primes that reported paying it, from FFATA subaward reports.

Companies it pays

13 companies · $2M reported

  1. BOSTON MEDICAL CENTER CORPORATION$474.8K
    BOSTON, MA · 2 subawards
  2. VITALANT$312.6K
    SCOTTSDALE, AZ · 1 subaward
  3. UNIVERSIDAD PERUANA CAYETANO HEREDIA$255K
    LIMA, PER · 1 subaward

Primes that pay it

No prime reported paying it.

Showing the top 3 of each list. Open the profile for potential partners and the full lists.

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 3, 2026, loaded Oct 3, 2026 · Subawards loaded from 2021.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. VITRUVIAN BIO, LLC$600K
    BALTIMORE, MD · 100.0% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. BIG EYE DIAGNOSTICS INC$599.6K−100% in FY2026
    SAN DIEGO, CA · 99.9% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. ENEPRET INCORPORATED$599.5K−100% in FY2026
    LEXINGTON, KY · 99.9% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 3, 2026, loaded Oct 3, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 3, 2026, loaded Oct 3, 2026.